PROFESSIONAL EDITION

The largest community of pharma leaders

Turn Therapeutics Receives Authorization to Commence Human Trial for COVID-19 Therapeutic Candidate

LOS ANGELES–(BUSINESS WIRE)–Turn Therapeutics, a biotechnology company specializing in advanced wound care and infection control, today announced the initiation of a two-part, four-arm, human safety and efficacy trial for its flagship product, Hexagen, to be used in the fight against COVID-19. This randomized, placebo-controlled trial will enroll approximately 100 mild to moderate COVID-19 patients and 50 healthcare workers across four leading hospitals in Panama, including internationally re

Source Business Wire Health: Pharmaceutical NewsRead More

Recent Articles